Endocrine Abstracts

Acromegaly is a rare endocrine disorder caused by growth hormone (GH) secreting pituitary adenoma. The treatment of choice is transsphenoidal surgery. In patients with persistent disease after surgery medical therapy is recommended. First-line medical treatment include first generation long-acting somatostatin analogs: octreotide LAR and lanreotide autogel. Recently, pasireotide – a second generation somatostatin analog has been investigated in patients with acromegaly.</...

Background: Thyroid-stimulating hormone (TSH) expressing tumors are one of the rarest pituitary adenomas and comprises 0.5–2% of all cases. To our knowledge, only four cases of thyrotropinoma in a pregnant women have been reported up to date.Case presentation: We present a case of 24-year old women who reported to gynecologist due to secondary amenorrhea and severe headaches. Commissioned laboratory test showed, among others, prolactin 31.0 ng/ml a...

Primary hypophysitis (PH) is a rare clinical entity usually presenting with headaches, pituitary deficiency, visual field defects and exceptionally with symptoms of cavernous sinus infiltration such as cranial nerve palsies. An internal carotid artery (ICA) occlusion is unusual complication of PH infiltrating the cavernous sinus. A 32-year old woman presented with a 4-year history of recurring headaches, right retro-orbital pain, periodic diplopia and secondary adren...

Introduction: The treatment of choice in persistent acromegaly after transsphenoidal adenomectomy is pharmacological treatment with first generation somatostatin analogs. They are effective in 25% to 45% of patients. Second generation somatostatin analog – pasireotide seems to be more effective.Aim: The aim of the study was to assess the efficacy and safety of pasireotide LAR in acromegaly patients resistant to first generation somatostatin analogs...

Introduction: The treatment of choice in acromegaly is a transsphenoidal surgery of a growth hormone (GH) - producing pituitary adenoma. In patients with persistent acromegaly after surgery medical treatment is recommended. First generation somatostatin analogs: lanreotide autogel and octreotide LAR are effective in 25% to 45% of patients depending on population and study protocol. Second-generation somatostatin analog – pasireotide LAR seems to be more effective. The pos...